Histogenics Corp. brought in more than $34 million in equity and debt financing after its acquisition of fellow Bay State firm ProChon Biotech Ltd.
The two companies merged in an all-stock deal that brings ProChon CEO Patrick O’Donnell into the Histogenics corner office.
O’Donnell told MassDevice.com last week that a deal has been in the works since the early part of 2011.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Histogenics has one product, an autologous knee cartilage regeneration system called NeoCart, in a pivotal Phase III trial. ProChon’s BioCart product, which uses a proprietary growth factor with a biocompatible scaffold for knee cartilage repair, is in a Phase II trial.
The company plans to pursue both tracks, O’Donnell said.
The funding came from sales of equity issued as a result of the merger and debt issued by financing the two businesses together, according to the SEC filing.
[Knee photo courtesy of Flickr user Larry Page]
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.